Observational Study of Medtronic Percept DBS in Parkinson's Disease

This study is looking at how the Medtronic Percept™ DBS system, used for Parkinson's disease, affects movement and brain activity. Researchers will observe people who already have this system implanted and have been using it for at least three months. They want to understand how brain signals (local field potentials or LFPs) relate to changes in walking and balance during daily activities. The study aims to see if there's a connection between these brain signals and how well you move, especially your leg function and posture. The main goals are to measure your walking speed, stride length, and brain activity after 30 days. This is an observational study, meaning there are no new treatments given. The study plans to enroll 36 participants.

Study design
This is an observational study, meaning no new treatments are given. It plans to include 36 participants.
What's involved
You would be observed for a minimum of 4 weeks, with measurements taken at 30 days.
Compensation
Not stated in the trial record.
Follow-up
Measurements for the main goals are taken at 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05656586

Udall Project 2 Aim 2A&C

Recruiting
Not specifiedAll AgesObservational
University of Minnesota
~36 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:observational-- no intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Peak negative power
Measured over 30 day
+3 more outcomes measured
Parkinson Disease

NCT05656586

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Minnesota

    Minneapolis, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Receiving DBS therapy in GP for treatment of PD
Implanted with Medtronic Percept DBS system
At least 3 months since initial activation of the neurostimulator
For the "At Home" experiment only: participants with DBS settings that are sensing compatible.

Exclusion

history of musculoskeletal disorders that significantly affects the ability to perform the motor tasks in the specific experiment in question
history of dementia or cognitive impairment
other significant neurological disorder as determined by the PI
post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment
lack of capacity to consent (as identified by MaCAT-CR)
  • Peak negative power30 day

    A servo-controlled ankle manipulandum will be used to obtain objective measures of resistance about the dorsiflexion/plantar flexion axis (range of motion approximately 5 deg. dorsiflexion to 30 deg. plantar flexion; frequency = 1.5 Hz). Two conditions will be tested: passive movement with and without an activation maneuver on the contralateral side (repetitive tapping of the toe or heel).

  • Stride length30 days

    The spatial and temporal parameters of overground steady-state gait will be assessed in the lab or derived from the wearable device (mPower)

  • Alpha power during standardized daily gait assessment30 days

    The participant will use their DBS device patient programmer to record a time stamp and capture LFPs using the implanted Medtronic Percept™ device during the standardized daily gait assessments.

  • cadence30 days

    The spatial and temporal parameters of overground steady-state gait will be assessed in the lab or derived from the wearable device (mPower)